Olmesartan

Generic Name
Olmesartan
Brand Names
Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
Drug Type
Small Molecule
Chemical Formula
C24H26N6O3
CAS Number
144689-24-7
Unique Ingredient Identifier
8W1IQP3U10
Background

Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...

Indication

Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...

Associated Conditions
Diabetic Nephropathy, Hypertension
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

First Posted Date
2008-06-12
Last Posted Date
2011-07-29
Lead Sponsor
Takeda
Target Recruit Count
1275
Registration Number
NCT00696241

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

First Posted Date
2008-06-12
Last Posted Date
2011-04-19
Lead Sponsor
Takeda
Target Recruit Count
1291
Registration Number
NCT00696436

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

First Posted Date
2008-05-13
Last Posted Date
2018-12-24
Lead Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Target Recruit Count
133
Registration Number
NCT00676845

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

First Posted Date
2008-04-01
Last Posted Date
2019-01-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
2500
Registration Number
NCT00649389

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

First Posted Date
2007-08-31
Last Posted Date
2020-08-04
Lead Sponsor
Novartis
Target Recruit Count
257
Registration Number
NCT00523744
Locations

30 sites in Germany

🇩🇪

Novartis Investigative Site, , Germany, Schwerin, Germany

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

Phase 3
Completed
Conditions
Chronic Heart Failure
Interventions
Drug: olmesartan medoxomil
First Posted Date
2006-12-29
Last Posted Date
2014-05-19
Lead Sponsor
Tohoku University
Target Recruit Count
1145
Registration Number
NCT00417222
Locations
🇯🇵

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai-city, Japan

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2006-12-19
Last Posted Date
2009-09-22
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
178
Registration Number
NCT00412932

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

First Posted Date
2006-11-23
Last Posted Date
2016-11-03
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
192
Registration Number
NCT00403481

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Phase 3
Completed
Conditions
Atherosclerosis
First Posted Date
2006-09-28
Last Posted Date
2023-06-01
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
210
Registration Number
NCT00382213

Olmesartan Medoxomil and Diabetic Nephropathy

First Posted Date
2006-08-15
Last Posted Date
2006-10-09
Lead Sponsor
Sankyo Pharma Gmbh
Target Recruit Count
300
Registration Number
NCT00362960
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy